Phoenix and Raven Become First Canadian Telehealth Platforms to Offer Generic Semaglutide Direct to Patients
Eligible Canadians can now access Health Canada–approved generic semaglutide directly, by prescription, starting at $124.99
Today, Phoenix and Raven, leading Canadian digital health providers, announced the launch of generic semaglutide for direct-to-patient access in Canada, making them the first telehealth platform in the country to bring this medication to customers. Phoenix and Raven are looking to set the new pricing for optimal access with orders starting at $124.99, delivered by prescription across Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521867755/en/
The launch follows Health Canada's recent approval on April 28, 2026, making Canada the first G7 country to offer a generic semaglutide. With multiple generic manufacturers now authorized to supply the Canadian market, today's launch signals the beginning of a new era of accessibility for a medication that has fundamentally reshaped conversations about chronic disease, weight, and preventive health.
